Artificial Intelligence and Amikacin Exposures Predictive of Outcomes in Multidrug-Resistant Tuberculosis Patients

Aminoglycosides such as amikacin continue to be part of the backbone of treatment of multidrug-resistant tuberculosis (MDR-TB). We measured amikacin concentrations in 28 MDR-TB patients in Botswana receiving amikacin therapy together with oral levofloxacin, ethionamide, cycloserine, and pyrazinamide...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Antimicrob Agents Chemother
Autors principals: Modongo, Chawangwa, Pasipanodya, Jotam G., Magazi, Beki T., Srivastava, Shashikant, Zetola, Nicola M., Williams, Scott M., Sirugo, Giorgio, Gumbo, Tawanda
Format: Artigo
Idioma:Inglês
Publicat: American Society for Microbiology 2016
Matèries:
Experimental Therapeutics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5038293/
https://ncbi.nlm.nih.gov/pubmed/27458224
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00962-16
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars